

DAPSONE Drug Specific Monitoring Document



TARGET AUDIENCE	Board-wide
PATIENT GROUP	All patients aged 12 years and older taking Dapsone

References

- British National Formulary (2024). *BNF / NICE*. [online] NICE. Available at: <https://bnf.nice.org.uk/>.
- Specialist Pharmacy Service (2021). *Medicines Monitoring*. [online] SPS - Specialist Pharmacy Service. Available at: <https://www.sps.nhs.uk/home/tools/drug-monitoring/>.
- Electronic Medicines Compendium (2019). *Home - electronic medicines compendium (emc)*. [online] Medicines.org.uk. Available at: <https://www.medicines.org.uk/emc>

Governance information for drug specific document

Lead Author(s):	Medicines Policy and Guidance Team
Endorsing Body:	Area Drug and Therapeutics Committee
Version Number:	V1.1
Approval date	18.06.2025
Review Date:	18.06.2026
Responsible Person (if different from lead author)	Kirsty Macfarlane/Mark Russell

DAPSONE Drug Specific Monitoring Document

Medication Name	DAPSONE
Actions by specialist clinician before Initiation	<ul style="list-style-type: none"> • FBC – correcting severe anaemia before starting • U&Es • LFTs • Reticulocyte count • G6PD level <p><i>For all drugs, specialist clinicians should consider whether vaccination/exclusion of other contraindications (including active infection), is required and arrange as appropriate.</i></p>
DIS actions on starting treatment and following dose titration during initiation period	<p>Every 2 weeks for one month, then monthly for 3 months</p> <ul style="list-style-type: none"> • FBC • U&Es • LFTs • Reticulocyte count
Ongoing monitoring in Primary Care once stable	<p>Every 3 months</p> <ul style="list-style-type: none"> • FBC • U&Es • LFTs • Reticulocyte count
Action if monitoring is outside reference range	<ul style="list-style-type: none"> • Seek advice from initiating specialist should results be outside reference range. • Reticulocyte count up to 4% acceptable in Hb stable. • If reticulocyte count >4% with drop in haemoglobin (by >20g/L or total Hb less than 100g/L) and/or breathlessness, contact specialist.
Actions to take if restarting medication after treatment break	<p>Actions needed may vary - consult specialist team for further guidance</p> <p>Patients should be referred by the specialist clinician to the drug initiation hub if re-titration or enhanced monitoring is required</p>

Uncontrolled when printed - access the most up to date version on www.nhsguidelines.scot.nhs.uk

Lead Author	Kirsty Macfarlane/Mark Russell	Date approved	18.06.2025
Version	V1.1	Review Date	18.06.2026

DAPSONE Drug Specific Monitoring Document

CONSULTATION AND DISTRIBUTION RECORD	
Contributing Author / Authors	Kirsty Macfarlane, Mark Russell, Kendal Paterson, Katrina Maroni
Consultation Process / Stakeholders:	LMC, GP Sub-committee, Jennifer Gibson, Karen Donaldson, Eimear Gordon, Anthony Carson, Richard Shearer, Rebecca Malley, Rosemary Beaton, Drug Initiation Service pharmacists, Acute specialist dermatology, pharmacists.
Distribution	Acute specialist consultants and pharmacists, Senior primary care pharmacists, all individuals involved with the Drug Initiation Service, LMC and GP sub-committee

CHANGE RECORD			
Date	Lead Author	Change	Version

Uncontrolled when printed - access the most up to date version on www.nhsguidelines.scot.nhs.uk

Lead Author	Kirsty Macfarlane/Mark Russell	Date approved	18.06.2025
Version	V1.1	Review Date	18.06.2026